

Global Peptide Drug Conjugate Market Research Report 2026(Status and Outlook)

<https://marketpublishers.com/r/GF72DFA428D0EN.html>

Date: March 2026

Pages: 146

Price: US\$ 2,980.00 (Single User License)

ID: GF72DFA428D0EN

Abstracts

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Peptide Drug Conjugate competitive dynamics, regional economic interdependencies, and supply chain reconfigurations. As an emerging cancer treatment method, peptide-drug conjugates can increase the targeting of drug delivery, improve efficacy and reduce side effects. In recent years, the research and development of peptide-drug conjugates has accelerated and gained market attention. The structure of peptide-drug conjugates is similar to that of antibody-drug conjugates, and only differs in the targeting carrier part. PDC drugs are composed of three parts: homing peptides, linkers and cytotoxic payloads. The three work together to target specific receptors of tumor cells.

The global Peptide Drug Conjugate market size was estimated at USD 76.4 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 37.20% during the forecast period.

This report offers a comprehensive and in-depth analysis of the global Peptide Drug Conjugate market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.

The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.

A significant focus of this report lies in the competitive landscape of the global Peptide Drug Conjugate market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.

In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Peptide Drug Conjugate market.

Global Peptide Drug Conjugate Market: Market Segmentation Analysis

This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.

A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.

Key Company

Bicycle Therapeutics
Cybrexa Therapeutics
Theratechnologies
Zhongshan Laibo Ruichen Biopharmaceutical
Beijing Shenogen Pharma Group
XINOGEN (HONG KONG) PHARMA
Lumosa Therapeutics
Shanghai Pharmaceuticals
Tianjin Conjustar Biotechnology
Gaorui Yaoye(Beijing)Technologies
Shanghai Huiyong Pharmaceutical
BrightGene Bio-Medical Technology

Market Segmentation (by Type)

Cell-penetrating Peptides (CPP)
Cell Targeting Peptides (CTP)
Others

Market Segmentation (by Application)

Breast Cancer
Pancreatic Cancer
Others

Geographic Segmentation

North America (USA, Canada, Mexico)
Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
South America (Brazil, Argentina, Columbia, Rest of South America)
The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study
Neutral perspective on the market performance
Recent industry trends and developments
Competitive landscape & strategies of key players
Potential & niche segments and regions exhibiting promising growth covered
Historical, current, and projected market size, in terms of value
In-depth analysis of the Peptide Drug Conjugate Market
Overview of the regional outlook of the Peptide Drug Conjugate Market:

Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Peptide Drug Conjugate Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 shares the main producing countries of Peptide Drug Conjugate, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.

Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.

Chapter 13 is the main points and conclusions of the report.

Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your competitors

You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents

The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly

Provision of market value data for each segment and sub-segment

Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market

Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region

Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled

Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players

The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions

Includes in-depth analysis of the market from various perspectives through Porter's five forces analysis

Provides insight into the market through Value Chain

Market dynamics scenario, along with growth opportunities of the market in the years to come

6-month post-sales analyst support

Customization of the Report

In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.

Contents

1 RESEARCH METHODOLOGY AND STATISTICAL SCOPE

- 1.1 Market Definition and Statistical Scope of Peptide Drug Conjugate
- 1.2 Key Market Segments
 - 1.2.1 Peptide Drug Conjugate Segment by Type
 - 1.2.2 Peptide Drug Conjugate Segment by Application
- 1.3 Methodology & Sources of Information
 - 1.3.1 Research Methodology
 - 1.3.2 Research Process
 - 1.3.3 Market Breakdown and Data Triangulation
 - 1.3.4 Base Year
 - 1.3.5 Report Assumptions & Caveats

2 PEPTIDE DRUG CONJUGATE MARKET OVERVIEW

- 2.1 Global Market Overview
 - 2.1.1 Global Peptide Drug Conjugate Market Size (M USD) Estimates and Forecasts (2020-2035)
 - 2.1.2 Global Peptide Drug Conjugate Sales Estimates and Forecasts (2020-2035)
- 2.2 Market Segment Executive Summary
- 2.3 Global Market Size by Region

3 PEPTIDE DRUG CONJUGATE MARKET COMPETITIVE LANDSCAPE

- 3.1 Company Assessment Quadrant
- 3.2 Global Peptide Drug Conjugate Product Life Cycle
- 3.3 Global Peptide Drug Conjugate Sales by Manufacturers (2020-2025)
- 3.4 Global Peptide Drug Conjugate Revenue Market Share by Manufacturers (2020-2025)
- 3.5 Peptide Drug Conjugate Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
- 3.6 Global Peptide Drug Conjugate Average Price by Manufacturers (2020-2025)
- 3.7 Manufacturers? Manufacturing Sites, Areas Served, and Product Types
- 3.8 Peptide Drug Conjugate Market Competitive Situation and Trends
 - 3.8.1 Peptide Drug Conjugate Market Concentration Rate
 - 3.8.2 Global 5 and 10 Largest Peptide Drug Conjugate Players Market Share by Revenue
 - 3.8.3 Mergers & Acquisitions, Expansion

4 PEPTIDE DRUG CONJUGATE INDUSTRY CHAIN ANALYSIS

- 4.1 Peptide Drug Conjugate Industry Chain Analysis
- 4.2 Market Overview of Key Raw Materials
- 4.3 Midstream Market Analysis
- 4.4 Downstream Customer Analysis

5 THE DEVELOPMENT AND DYNAMICS OF PEPTIDE DRUG CONJUGATE MARKET

- 5.1 Key Development Trends
- 5.2 Driving Factors
- 5.3 Market Challenges
- 5.4 Industry News
 - 5.4.1 New Product Developments
 - 5.4.2 Mergers & Acquisitions
 - 5.4.3 Expansions
 - 5.4.4 Collaboration/Supply Contracts
- 5.5 PEST Analysis
 - 5.5.1 Industry Policies Analysis
 - 5.5.2 Economic Environment Analysis
 - 5.5.3 Social Environment Analysis
 - 5.5.4 Technological Environment Analysis
- 5.6 Global Peptide Drug Conjugate Market Porter's Five Forces Analysis
 - 5.6.1 Global Trade Frictions
 - 5.6.2 U.S. Tariff Policy ? April 2025
 - 5.6.3 Global Trade Frictions and Their Impacts to Peptide Drug Conjugate Market
- 5.7 ESG Ratings of Leading Companies

6 PEPTIDE DRUG CONJUGATE MARKET SEGMENTATION BY TYPE

- 6.1 Evaluation Matrix of Segment Market Development Potential (Type)
- 6.2 Global Peptide Drug Conjugate Sales Market Share by Type (2020-2025)
- 6.3 Global Peptide Drug Conjugate Market Size by Type (2020-2025)
- 6.4 Global Peptide Drug Conjugate Price by Type (2020-2025)

7 PEPTIDE DRUG CONJUGATE MARKET SEGMENTATION BY APPLICATION

- 7.1 Evaluation Matrix of Segment Market Development Potential (Application)
- 7.2 Global Peptide Drug Conjugate Market Sales by Application (2020-2025)
- 7.3 Global Peptide Drug Conjugate Market Size (M USD) by Application (2020-2025)
- 7.4 Global Peptide Drug Conjugate Sales Growth Rate by Application (2020-2025)

8 PEPTIDE DRUG CONJUGATE MARKET SALES BY REGION

- 8.1 Global Peptide Drug Conjugate Sales by Region
 - 8.1.1 Global Peptide Drug Conjugate Sales by Region
 - 8.1.2 Global Peptide Drug Conjugate Sales Market Share by Region
- 8.2 Global Peptide Drug Conjugate Market Size by Region
 - 8.2.1 Global Peptide Drug Conjugate Market Size by Region
 - 8.2.2 Global Peptide Drug Conjugate Market Size by Region
- 8.3 North America
 - 8.3.1 North America Peptide Drug Conjugate Sales by Country
 - 8.3.2 North America Peptide Drug Conjugate Market Size by Country
 - 8.3.3 U.S. Market Overview
 - 8.3.4 Canada Market Overview
 - 8.3.5 Mexico Market Overview
- 8.4 Europe
 - 8.4.1 Europe Peptide Drug Conjugate Sales by Country
 - 8.4.2 Europe Peptide Drug Conjugate Market Size by Country
 - 8.4.3 Germany Market Overview
 - 8.4.4 France Market Overview
 - 8.4.5 U.K. Market Overview
 - 8.4.6 Italy Market Overview
 - 8.4.7 Spain Market Overview
- 8.5 Asia Pacific
 - 8.5.1 Asia Pacific Peptide Drug Conjugate Sales by Region
 - 8.5.2 Asia Pacific Peptide Drug Conjugate Market Size by Region
 - 8.5.3 China Market Overview
 - 8.5.4 Japan Market Overview
 - 8.5.5 South Korea Market Overview
 - 8.5.6 India Market Overview
 - 8.5.7 Southeast Asia Market Overview
- 8.6 South America
 - 8.6.1 South America Peptide Drug Conjugate Sales by Country
 - 8.6.2 South America Peptide Drug Conjugate Market Size by Country
 - 8.6.3 Brazil Market Overview

- 8.6.4 Argentina Market Overview
- 8.6.5 Columbia Market Overview
- 8.7 Middle East and Africa
 - 8.7.1 Middle East and Africa Peptide Drug Conjugate Sales by Region
 - 8.7.2 Middle East and Africa Peptide Drug Conjugate Market Size by Region
 - 8.7.3 Saudi Arabia Market Overview
 - 8.7.4 UAE Market Overview
 - 8.7.5 Egypt Market Overview
 - 8.7.6 Nigeria Market Overview
 - 8.7.7 South Africa Market Overview

9 PEPTIDE DRUG CONJUGATE MARKET PRODUCTION BY REGION

- 9.1 Global Production of Peptide Drug Conjugate by Region(2020-2025)
- 9.2 Global Peptide Drug Conjugate Revenue Market Share by Region (2020-2025)
- 9.3 Global Peptide Drug Conjugate Production, Revenue, Price and Gross Margin (2020-2025)
- 9.4 North America Peptide Drug Conjugate Production
 - 9.4.1 North America Peptide Drug Conjugate Production Growth Rate (2020-2025)
 - 9.4.2 North America Peptide Drug Conjugate Production, Revenue, Price and Gross Margin (2020-2025)
- 9.5 Europe Peptide Drug Conjugate Production
 - 9.5.1 Europe Peptide Drug Conjugate Production Growth Rate (2020-2025)
 - 9.5.2 Europe Peptide Drug Conjugate Production, Revenue, Price and Gross Margin (2020-2025)
- 9.6 Japan Peptide Drug Conjugate Production (2020-2025)
 - 9.6.1 Japan Peptide Drug Conjugate Production Growth Rate (2020-2025)
 - 9.6.2 Japan Peptide Drug Conjugate Production, Revenue, Price and Gross Margin (2020-2025)
- 9.7 China Peptide Drug Conjugate Production (2020-2025)
 - 9.7.1 China Peptide Drug Conjugate Production Growth Rate (2020-2025)
 - 9.7.2 China Peptide Drug Conjugate Production, Revenue, Price and Gross Margin (2020-2025)

10 KEY COMPANIES PROFILE

- 10.1 Bicycle Therapeutics
 - 10.1.1 Bicycle Therapeutics Basic Information
 - 10.1.2 Bicycle Therapeutics Peptide Drug Conjugate Product Overview

- 10.1.3 Bicycle Therapeutics Peptide Drug Conjugate Product Market Performance
- 10.1.4 Bicycle Therapeutics Business Overview
- 10.1.5 Bicycle Therapeutics SWOT Analysis
- 10.1.6 Bicycle Therapeutics Recent Developments
- 10.2 Cybrexa Therapeutics
 - 10.2.1 Cybrexa Therapeutics Basic Information
 - 10.2.2 Cybrexa Therapeutics Peptide Drug Conjugate Product Overview
 - 10.2.3 Cybrexa Therapeutics Peptide Drug Conjugate Product Market Performance
 - 10.2.4 Cybrexa Therapeutics Business Overview
 - 10.2.5 Cybrexa Therapeutics SWOT Analysis
 - 10.2.6 Cybrexa Therapeutics Recent Developments
- 10.3 Theratechnologies
 - 10.3.1 Theratechnologies Basic Information
 - 10.3.2 Theratechnologies Peptide Drug Conjugate Product Overview
 - 10.3.3 Theratechnologies Peptide Drug Conjugate Product Market Performance
 - 10.3.4 Theratechnologies Business Overview
 - 10.3.5 Theratechnologies SWOT Analysis
 - 10.3.6 Theratechnologies Recent Developments
- 10.4 Zhongshan Laibo Ruichen Biopharmaceutical
 - 10.4.1 Zhongshan Laibo Ruichen Biopharmaceutical Basic Information
 - 10.4.2 Zhongshan Laibo Ruichen Biopharmaceutical Peptide Drug Conjugate Product Overview
 - 10.4.3 Zhongshan Laibo Ruichen Biopharmaceutical Peptide Drug Conjugate Product Market Performance
 - 10.4.4 Zhongshan Laibo Ruichen Biopharmaceutical Business Overview
 - 10.4.5 Zhongshan Laibo Ruichen Biopharmaceutical Recent Developments
- 10.5 Beijing Shenogen Pharma Group
 - 10.5.1 Beijing Shenogen Pharma Group Basic Information
 - 10.5.2 Beijing Shenogen Pharma Group Peptide Drug Conjugate Product Overview
 - 10.5.3 Beijing Shenogen Pharma Group Peptide Drug Conjugate Product Market Performance
 - 10.5.4 Beijing Shenogen Pharma Group Business Overview
 - 10.5.5 Beijing Shenogen Pharma Group Recent Developments
- 10.6 XINOGEN (HONG KONG) PHARMA
 - 10.6.1 XINOGEN (HONG KONG) PHARMA Basic Information
 - 10.6.2 XINOGEN (HONG KONG) PHARMA Peptide Drug Conjugate Product Overview
 - 10.6.3 XINOGEN (HONG KONG) PHARMA Peptide Drug Conjugate Product Market Performance

- 10.6.4 XINOGEN (HONG KONG) PHARMA Business Overview
- 10.6.5 XINOGEN (HONG KONG) PHARMA Recent Developments
- 10.7 Lumosa Therapeutics
 - 10.7.1 Lumosa Therapeutics Basic Information
 - 10.7.2 Lumosa Therapeutics Peptide Drug Conjugate Product Overview
 - 10.7.3 Lumosa Therapeutics Peptide Drug Conjugate Product Market Performance
 - 10.7.4 Lumosa Therapeutics Business Overview
 - 10.7.5 Lumosa Therapeutics Recent Developments
- 10.8 Shanghai Pharmaceuticals
 - 10.8.1 Shanghai Pharmaceuticals Basic Information
 - 10.8.2 Shanghai Pharmaceuticals Peptide Drug Conjugate Product Overview
 - 10.8.3 Shanghai Pharmaceuticals Peptide Drug Conjugate Product Market Performance
 - 10.8.4 Shanghai Pharmaceuticals Business Overview
 - 10.8.5 Shanghai Pharmaceuticals Recent Developments
- 10.9 Tianjin Conjustar Biotechnology
 - 10.9.1 Tianjin Conjustar Biotechnology Basic Information
 - 10.9.2 Tianjin Conjustar Biotechnology Peptide Drug Conjugate Product Overview
 - 10.9.3 Tianjin Conjustar Biotechnology Peptide Drug Conjugate Product Market Performance
 - 10.9.4 Tianjin Conjustar Biotechnology Business Overview
 - 10.9.5 Tianjin Conjustar Biotechnology Recent Developments
- 10.10 Gaorui Yaoye(Beijing)Technologies
 - 10.10.1 Gaorui Yaoye(Beijing)Technologies Basic Information
 - 10.10.2 Gaorui Yaoye(Beijing)Technologies Peptide Drug Conjugate Product Overview
 - 10.10.3 Gaorui Yaoye(Beijing)Technologies Peptide Drug Conjugate Product Market Performance
 - 10.10.4 Gaorui Yaoye(Beijing)Technologies Business Overview
 - 10.10.5 Gaorui Yaoye(Beijing)Technologies Recent Developments
- 10.11 Shanghai Huiyong Pharmaceutical
 - 10.11.1 Shanghai Huiyong Pharmaceutical Basic Information
 - 10.11.2 Shanghai Huiyong Pharmaceutical Peptide Drug Conjugate Product Overview
 - 10.11.3 Shanghai Huiyong Pharmaceutical Peptide Drug Conjugate Product Market Performance
 - 10.11.4 Shanghai Huiyong Pharmaceutical Business Overview
 - 10.11.5 Shanghai Huiyong Pharmaceutical Recent Developments
- 10.12 BrightGene Bio-Medical Technology
 - 10.12.1 BrightGene Bio-Medical Technology Basic Information

10.12.2 BrightGene Bio-Medical Technology Peptide Drug Conjugate Product Overview

10.12.3 BrightGene Bio-Medical Technology Peptide Drug Conjugate Product Market Performance

10.12.4 BrightGene Bio-Medical Technology Business Overview

10.12.5 BrightGene Bio-Medical Technology Recent Developments

11 PEPTIDE DRUG CONJUGATE MARKET FORECAST BY REGION

11.1 Global Peptide Drug Conjugate Market Size Forecast

11.2 Global Peptide Drug Conjugate Market Forecast by Region

11.2.1 North America Market Size Forecast by Country

11.2.2 Europe Peptide Drug Conjugate Market Size Forecast by Country

11.2.3 Asia Pacific Peptide Drug Conjugate Market Size Forecast by Region

11.2.4 South America Peptide Drug Conjugate Market Size Forecast by Country

11.2.5 Middle East and Africa Forecasted Sales of Peptide Drug Conjugate by Country

12 FORECAST MARKET BY TYPE AND BY APPLICATION (2026-2035)

12.1 Global Peptide Drug Conjugate Market Forecast by Type (2026-2035)

12.1.1 Global Forecasted Sales of Peptide Drug Conjugate by Type (2026-2035)

12.1.2 Global Peptide Drug Conjugate Market Size Forecast by Type (2026-2035)

12.1.3 Global Forecasted Price of Peptide Drug Conjugate by Type (2026-2035)

12.2 Global Peptide Drug Conjugate Market Forecast by Application (2026-2035)

12.2.1 Global Peptide Drug Conjugate Sales (K MT) Forecast by Application

12.2.2 Global Peptide Drug Conjugate Market Size (M USD) Forecast by Application (2026-2035)

13 CONCLUSION AND KEY FINDINGS

List Of Tables

LIST OF TABLES

- Table 1. Introduction of the Type
- Table 2. Introduction of the Application
- Table 3. Global Peptide Drug Conjugate Market Size by Type (M USD)
- Table 4. Global Peptide Drug Conjugate Market Size by Application
- Table 5. Peptide Drug Conjugate Market Size Comparison by Region (M USD)
- Table 6. Global Peptide Drug Conjugate Sales (K MT) by Manufacturers (2020-2025)
- Table 7. Global Peptide Drug Conjugate Sales Market Share by Manufacturers (2020-2025)
- Table 8. Global Peptide Drug Conjugate Revenue (M USD) by Manufacturers (2020-2025)
- Table 9. Global Peptide Drug Conjugate Revenue Share by Manufacturers (2020-2025)
- Table 10. Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Peptide Drug Conjugate as of 2025)
- Table 11. Global Market Peptide Drug Conjugate Average Price (USD/KG) of Key Manufacturers (2020-2025)
- Table 12. Manufacturers? Manufacturing Sites, Areas Served
- Table 13. Manufacturers? Product Type
- Table 14. Global Peptide Drug Conjugate Manufacturers Market Concentration Ratio (CR5 and HHI)
- Table 15. Mergers & Acquisitions, Expansion Plans
- Table 16. Market Overview of Key Raw Materials
- Table 17. Midstream Market Analysis
- Table 18. Downstream Customer Analysis
- Table 19. Key Development Trends
- Table 20. Driving Factors
- Table 21. Peptide Drug Conjugate Market Challenges
- Table 22. Goldman Sachs' forecast real GDP growth rate for 2025-2026
- Table 23. S&P Global ' Forecast Real GDP Growth Rate For 2025-2027
- Table 24. World Bank ' Forecast Real GDP Growth Rate For 2025-2026
- Table 25. The Tariff Rates Imposed by the United States on Major Commodity Trading Countries
- Table 26. Global Peptide Drug Conjugate Sales by Type (K MT)
- Table 27. Global Peptide Drug Conjugate Market Size by Type (M USD)
- Table 28. Global Peptide Drug Conjugate Sales (K MT) by Type (2020-2025)
- Table 29. Global Peptide Drug Conjugate Sales Market Share by Type (2020-2025)

Table 30. Global Peptide Drug Conjugate Market Size (M USD) by Type (2020-2025)

Table 31. Global Peptide Drug Conjugate Market Share by Type (2020-2025)

Table 32. Global Peptide Drug Conjugate Price (USD/KG) by Type (2020-2025)

Table 33. Global Peptide Drug Conjugate Sales (K MT) by Application

Table 34. Global Peptide Drug Conjugate Market Size by Application

Table 35. Global Peptide Drug Conjugate Sales by Application (2020-2025) & (K MT)

Table 36. Global Peptide Drug Conjugate Sales Market Share by Application (2020-2025)

Table 37. Global Peptide Drug Conjugate Market Size by Application (2020-2025) & (M USD)

Table 38. Global Peptide Drug Conjugate Market Share by Application (2020-2025)

Table 39. Global Peptide Drug Conjugate Sales Growth Rate by Application (2020-2025)

Table 40. Global Peptide Drug Conjugate Sales by Region (2020-2025) & (K MT)

Table 41. Global Peptide Drug Conjugate Sales Market Share by Region (2020-2025)

Table 42. Global Peptide Drug Conjugate Market Size by Region (2020-2025) & (M USD)

Table 43. Global Peptide Drug Conjugate Market Size by Region (2020-2025)

Table 44. North America Peptide Drug Conjugate Sales by Country (2020-2025) & (K MT)

Table 45. North America Peptide Drug Conjugate Market Size by Country (2020-2025) & (M USD)

Table 46. Europe Peptide Drug Conjugate Sales by Country (2020-2025) & (K MT)

Table 47. Europe Peptide Drug Conjugate Market Size by Country (2020-2025) & (M USD)

Table 48. Asia Pacific Peptide Drug Conjugate Sales by Region (2020-2025) & (K MT)

Table 49. Asia Pacific Peptide Drug Conjugate Market Size by Region (2020-2025) & (M USD)

Table 50. South America Peptide Drug Conjugate Sales by Country (2020-2025) & (K MT)

Table 51. South America Peptide Drug Conjugate Market Size by Country (2020-2025) & (M USD)

Table 52. Middle East and Africa Peptide Drug Conjugate Sales by Region (2020-2025) & (K MT)

Table 53. Middle East and Africa Peptide Drug Conjugate Market Size by Region (2020-2025) & (M USD)

Table 54. Global Peptide Drug Conjugate Production (K MT) by Region(2020-2025)

Table 55. Global Peptide Drug Conjugate Revenue (US\$ Million) by Region (2020-2025)

- Table 56. Global Peptide Drug Conjugate Revenue Market Share by Region (2020-2025)
- Table 57. Global Peptide Drug Conjugate Production (K MT), Revenue (US\$ Million), Price (USD/KG) and Gross Margin (2020-2025)
- Table 58. North America Peptide Drug Conjugate Production (K MT), Revenue (US\$ Million), Price (USD/KG) and Gross Margin (2020-2025)
- Table 59. Europe Peptide Drug Conjugate Production (K MT), Revenue (US\$ Million), Price (USD/KG) and Gross Margin (2020-2025)
- Table 60. Japan Peptide Drug Conjugate Production (K MT), Revenue (US\$ Million), Price (USD/KG) and Gross Margin (2020-2025)
- Table 61. China Peptide Drug Conjugate Production (K MT), Revenue (US\$ Million), Price (USD/KG) and Gross Margin (2020-2025)
- Table 62. Bicycle Therapeutics Basic Information
- Table 63. Bicycle Therapeutics Peptide Drug Conjugate Product Overview
- Table 64. Bicycle Therapeutics Peptide Drug Conjugate Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
- Table 65. Bicycle Therapeutics Business Overview
- Table 66. Bicycle Therapeutics SWOT Analysis
- Table 67. Bicycle Therapeutics Recent Developments
- Table 68. Cybrexa Therapeutics Basic Information
- Table 69. Cybrexa Therapeutics Peptide Drug Conjugate Product Overview
- Table 70. Cybrexa Therapeutics Peptide Drug Conjugate Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
- Table 71. Cybrexa Therapeutics Business Overview
- Table 72. Cybrexa Therapeutics SWOT Analysis
- Table 73. Cybrexa Therapeutics Recent Developments
- Table 74. Theratechnologies Basic Information
- Table 75. Theratechnologies Peptide Drug Conjugate Product Overview
- Table 76. Theratechnologies Peptide Drug Conjugate Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
- Table 77. Theratechnologies Business Overview
- Table 78. Theratechnologies SWOT Analysis
- Table 79. Theratechnologies Recent Developments
- Table 80. Zhongshan Laibo Ruichen Biopharmaceutical Basic Information
- Table 81. Zhongshan Laibo Ruichen Biopharmaceutical Peptide Drug Conjugate Product Overview
- Table 82. Zhongshan Laibo Ruichen Biopharmaceutical Peptide Drug Conjugate Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
- Table 83. Zhongshan Laibo Ruichen Biopharmaceutical Business Overview

- Table 84. Zhongshan Laibo Ruichen Biopharmaceutical Recent Developments
- Table 85. Beijing Shenogen Pharma Group Basic Information
- Table 86. Beijing Shenogen Pharma Group Peptide Drug Conjugate Product Overview
- Table 87. Beijing Shenogen Pharma Group Peptide Drug Conjugate Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
- Table 88. Beijing Shenogen Pharma Group Business Overview
- Table 89. Beijing Shenogen Pharma Group Recent Developments
- Table 90. XINOGEN (HONG KONG) PHARMA Basic Information
- Table 91. XINOGEN (HONG KONG) PHARMA Peptide Drug Conjugate Product Overview
- Table 92. XINOGEN (HONG KONG) PHARMA Peptide Drug Conjugate Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
- Table 93. XINOGEN (HONG KONG) PHARMA Business Overview
- Table 94. XINOGEN (HONG KONG) PHARMA Recent Developments
- Table 95. Lumosa Therapeutics Basic Information
- Table 96. Lumosa Therapeutics Peptide Drug Conjugate Product Overview
- Table 97. Lumosa Therapeutics Peptide Drug Conjugate Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
- Table 98. Lumosa Therapeutics Business Overview
- Table 99. Lumosa Therapeutics Recent Developments
- Table 100. Shanghai Pharmaceuticals Basic Information
- Table 101. Shanghai Pharmaceuticals Peptide Drug Conjugate Product Overview
- Table 102. Shanghai Pharmaceuticals Peptide Drug Conjugate Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
- Table 103. Shanghai Pharmaceuticals Business Overview
- Table 104. Shanghai Pharmaceuticals Recent Developments
- Table 105. Tianjin Conjustar Biotechnology Basic Information
- Table 106. Tianjin Conjustar Biotechnology Peptide Drug Conjugate Product Overview
- Table 107. Tianjin Conjustar Biotechnology Peptide Drug Conjugate Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
- Table 108. Tianjin Conjustar Biotechnology Business Overview
- Table 109. Tianjin Conjustar Biotechnology Recent Developments
- Table 110. Gaorui Yaoye(Beijing)Technologies Basic Information
- Table 111. Gaorui Yaoye(Beijing)Technologies Peptide Drug Conjugate Product Overview
- Table 112. Gaorui Yaoye(Beijing)Technologies Peptide Drug Conjugate Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)
- Table 113. Gaorui Yaoye(Beijing)Technologies Business Overview
- Table 114. Gaorui Yaoye(Beijing)Technologies Recent Developments

Table 115. Shanghai Huiyong Pharmaceutical Basic Information

Table 116. Shanghai Huiyong Pharmaceutical Peptide Drug Conjugate Product Overview

Table 117. Shanghai Huiyong Pharmaceutical Peptide Drug Conjugate Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 118. Shanghai Huiyong Pharmaceutical Business Overview

Table 119. Shanghai Huiyong Pharmaceutical Recent Developments

Table 120. BrightGene Bio-Medical Technology Basic Information

Table 121. BrightGene Bio-Medical Technology Peptide Drug Conjugate Product Overview

Table 122. BrightGene Bio-Medical Technology Peptide Drug Conjugate Sales (K MT), Revenue (M USD), Price (USD/KG) and Gross Margin (2020-2025)

Table 123. BrightGene Bio-Medical Technology Business Overview

Table 124. BrightGene Bio-Medical Technology Recent Developments

Table 125. Global Peptide Drug Conjugate Sales Forecast by Region (2026-2035) & (K MT)

Table 126. Global Peptide Drug Conjugate Market Size Forecast by Region (2026-2035) & (M USD)

Table 127. North America Peptide Drug Conjugate Sales Forecast by Country (2026-2035) & (K MT)

Table 128. North America Peptide Drug Conjugate Market Size Forecast by Country (2026-2035) & (M USD)

Table 129. Europe Peptide Drug Conjugate Sales Forecast by Country (2026-2035) & (K MT)

Table 130. Europe Peptide Drug Conjugate Market Size Forecast by Country (2026-2035) & (M USD)

Table 131. Asia Pacific Peptide Drug Conjugate Sales Forecast by Region (2026-2035) & (K MT)

Table 132. Asia Pacific Peptide Drug Conjugate Market Size Forecast by Region (2026-2035) & (M USD)

Table 133. South America Peptide Drug Conjugate Sales Forecast by Country (2026-2035) & (K MT)

Table 134. South America Peptide Drug Conjugate Market Size Forecast by Country (2026-2035) & (M USD)

Table 135. Middle East and Africa Peptide Drug Conjugate Sales Forecast by Country (2026-2035) & (Units)

Table 136. Middle East and Africa Peptide Drug Conjugate Market Size Forecast by Country (2026-2035) & (M USD)

Table 137. Global Peptide Drug Conjugate Sales Forecast by Type (2026-2035) & (K

MT)

Table 138. Global Peptide Drug Conjugate Market Size Forecast by Type (2026-2035) & (M USD)

Table 139. Global Peptide Drug Conjugate Price Forecast by Type (2026-2035) & (USD/KG)

Table 140. Global Peptide Drug Conjugate Sales (K MT) Forecast by Application (2026-2035)

Table 141. Global Peptide Drug Conjugate Market Size Forecast by Application (2026-2035) & (M USD)

List Of Figures

LIST OF FIGURES

- Figure 1. Product Picture of Peptide Drug Conjugate
- Figure 2. Data Triangulation
- Figure 3. Key Caveats
- Figure 4. Global Peptide Drug Conjugate Market Size (M USD), 2025-2035
- Figure 5. Global Peptide Drug Conjugate Market Size (M USD) (2020-2035)
- Figure 6. Global Peptide Drug Conjugate Sales (K MT) & (2020-2035)
- Figure 7. Evaluation Matrix of Segment Market Development Potential (Type)
- Figure 8. Evaluation Matrix of Segment Market Development Potential (Application)
- Figure 9. Evaluation Matrix of Regional Market Development Potential
- Figure 10. Peptide Drug Conjugate Market Size by Country (M USD)
- Figure 11. Company Assessment Quadrant
- Figure 12. Global Peptide Drug Conjugate Product Life Cycle
- Figure 13. Peptide Drug Conjugate Sales Share by Manufacturers in 2025
- Figure 14. Global Peptide Drug Conjugate Revenue Share by Manufacturers in 2025
- Figure 15. Peptide Drug Conjugate Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2025
- Figure 16. Global Market Peptide Drug Conjugate Average Price (USD/KG) of Key Manufacturers in 2025
- Figure 17. The Global 5 and 10 Largest Players: Market Share by Peptide Drug Conjugate Revenue in 2025
- Figure 18. Industry Chain Map of Peptide Drug Conjugate
- Figure 19. Global Peptide Drug Conjugate Market PEST Analysis
- Figure 20. Global Peptide Drug Conjugate Market Porter's Five Forces Analysis
- Figure 21. Global Merchandise Trade as a Percentage Of GDP
- Figure 22. US - Imports of Goods by Country
- Figure 23. China Exports by Country
- Figure 24. ESG Rating Distribution of The Leading Company Compared With Its Peers
- Figure 25. Evaluation Matrix of Segment Market Development Potential (Type)
- Figure 26. Global Peptide Drug Conjugate Market Share by Type
- Figure 27. Sales Market Share of Peptide Drug Conjugate by Type (2020-2025)
- Figure 28. Sales Market Share of Peptide Drug Conjugate by Type in 2025
- Figure 29. Market Share of Peptide Drug Conjugate by Type (2020-2025)
- Figure 30. Market Share of Peptide Drug Conjugate by Type in 2025
- Figure 31. Evaluation Matrix of Segment Market Development Potential (Application)
- Figure 32. Global Peptide Drug Conjugate Market Share by Application

Figure 33. Global Peptide Drug Conjugate Sales Market Share by Application (2020-2025)

Figure 34. Global Peptide Drug Conjugate Sales Market Share by Application in 2025

Figure 35. Global Peptide Drug Conjugate Market Share by Application (2020-2025)

Figure 36. Global Peptide Drug Conjugate Market Share by Application in 2025

Figure 37. Global Peptide Drug Conjugate Sales Growth Rate by Application (2020-2025)

Figure 38. Global Peptide Drug Conjugate Sales Market Share by Region (2020-2025)

Figure 39. Global Peptide Drug Conjugate Market Size by Region (2020-2025)

Figure 40. North America Peptide Drug Conjugate Sales and Growth Rate (2020-2025) & (K MT)

Figure 41. North America Peptide Drug Conjugate Sales and Growth Rate (2020-2025) & (K MT)

Figure 42. North America Peptide Drug Conjugate Sales Market Share by Country in 2024

Figure 43. North America Peptide Drug Conjugate Market Size and Growth Rate (2020-2025) & (M USD)

Figure 44. North America Peptide Drug Conjugate Market Size by Country in 2024

Figure 45. U.S. Peptide Drug Conjugate Sales and Growth Rate (2020-2025) & (K MT)

Figure 46. U.S. Peptide Drug Conjugate Market Size and Growth Rate (2020-2025) & (M USD)

Figure 47. Canada Peptide Drug Conjugate Sales (K MT) and Growth Rate (2020-2025)

Figure 48. Canada Peptide Drug Conjugate Market Size (M USD) and Growth Rate (2020-2025)

Figure 49. Mexico Peptide Drug Conjugate Sales (Units) and Growth Rate (2020-2025)

Figure 50. Mexico Peptide Drug Conjugate Market Size (Units) and Growth Rate (2020-2025)

Figure 51. Europe Peptide Drug Conjugate Sales and Growth Rate (2020-2025) & (K MT)

Figure 52. Europe Peptide Drug Conjugate Sales Market Share by Country in 2024

Figure 53. Europe Peptide Drug Conjugate Market Size and Growth Rate (2020-2025) & (M USD)

Figure 54. Europe Peptide Drug Conjugate Market Size by Country in 2024

Figure 55. Germany Peptide Drug Conjugate Sales and Growth Rate (2020-2025) & (K MT)

Figure 56. Germany Peptide Drug Conjugate Market Size and Growth Rate (2020-2025) & (M USD)

Figure 57. France Peptide Drug Conjugate Sales and Growth Rate (2020-2025) & (K MT)

Figure 58. France Peptide Drug Conjugate Market Size and Growth Rate (2020-2025) & (M USD)

Figure 59. U.K. Peptide Drug Conjugate Sales and Growth Rate (2020-2025) & (K MT)

Figure 60. U.K. Peptide Drug Conjugate Market Size and Growth Rate (2020-2025) & (M USD)

Figure 61. Italy Peptide Drug Conjugate Sales and Growth Rate (2020-2025) & (K MT)

Figure 62. Italy Peptide Drug Conjugate Market Size and Growth Rate (2020-2025) & (M USD)

Figure 63. Spain Peptide Drug Conjugate Sales and Growth Rate (2020-2025) & (K MT)

Figure 64. Spain Peptide Drug Conjugate Market Size and Growth Rate (2020-2025) & (M USD)

Figure 65. Asia Pacific Peptide Drug Conjugate Sales and Growth Rate (K MT)

Figure 66. Asia Pacific Peptide Drug Conjugate Sales Market Share by Region in 2024

Figure 67. Asia Pacific Peptide Drug Conjugate Market Size by Region in 2024

Figure 68. China Peptide Drug Conjugate Sales and Growth Rate (2020-2025) & (K MT)

Figure 69. China Peptide Drug Conjugate Market Size and Growth Rate (2020-2025) & (M USD)

Figure 70. Japan Peptide Drug Conjugate Sales and Growth Rate (2020-2025) & (K MT)

Figure 71. Japan Peptide Drug Conjugate Market Size and Growth Rate (2020-2025) & (M USD)

Figure 72. South Korea Peptide Drug Conjugate Sales and Growth Rate (2020-2025) & (K MT)

Figure 73. South Korea Peptide Drug Conjugate Market Size and Growth Rate (2020-2025) & (M USD)

Figure 74. India Peptide Drug Conjugate Sales and Growth Rate (2020-2025) & (K MT)

Figure 75. India Peptide Drug Conjugate Market Size and Growth Rate (2020-2025) & (M USD)

Figure 76. Southeast Asia Peptide Drug Conjugate Sales and Growth Rate (2020-2025) & (K MT)

Figure 77. Southeast Asia Peptide Drug Conjugate Market Size and Growth Rate (2020-2025) & (M USD)

Figure 78. South America Peptide Drug Conjugate Sales and Growth Rate (K MT)

Figure 79. South America Peptide Drug Conjugate Sales Market Share by Country in 2024

Figure 80. South America Peptide Drug Conjugate Market Size and Growth Rate (M USD)

Figure 81. South America Peptide Drug Conjugate Market Size by Country in 2024

Figure 82. Brazil Peptide Drug Conjugate Sales and Growth Rate (2020-2025) & (K MT)

- Figure 83. Brazil Peptide Drug Conjugate Market Size and Growth Rate (2020-2025) & (M USD)
- Figure 84. Argentina Peptide Drug Conjugate Sales and Growth Rate (2020-2025) & (K MT)
- Figure 85. Argentina Peptide Drug Conjugate Market Size and Growth Rate (2020-2025) & (M USD)
- Figure 86. Columbia Peptide Drug Conjugate Sales and Growth Rate (2020-2025) & (K MT)
- Figure 87. Columbia Peptide Drug Conjugate Market Size and Growth Rate (2020-2025) & (M USD)
- Figure 88. Middle East and Africa Peptide Drug Conjugate Sales and Growth Rate (K MT)
- Figure 89. Middle East and Africa Peptide Drug Conjugate Sales Market Share by Region in 2024
- Figure 90. Middle East and Africa Peptide Drug Conjugate Market Size and Growth Rate (M USD)
- Figure 91. Middle East and Africa Peptide Drug Conjugate Market Size by Region in 2024
- Figure 92. Saudi Arabia Peptide Drug Conjugate Sales and Growth Rate (2020-2025) & (K MT)
- Figure 93. Saudi Arabia Peptide Drug Conjugate Market Size and Growth Rate (2020-2025) & (M USD)
- Figure 94. UAE Peptide Drug Conjugate Sales and Growth Rate (2020-2025) & (K MT)
- Figure 95. UAE Peptide Drug Conjugate Market Size and Growth Rate (2020-2025) & (M USD)
- Figure 96. Egypt Peptide Drug Conjugate Sales and Growth Rate (2020-2025) & (K MT)
- Figure 97. Egypt Peptide Drug Conjugate Market Size and Growth Rate (2020-2025) & (M USD)
- Figure 98. Nigeria Peptide Drug Conjugate Sales and Growth Rate (2020-2025) & (K MT)
- Figure 99. Nigeria Peptide Drug Conjugate Market Size and Growth Rate (2020-2025) & (M USD)
- Figure 100. South Africa Peptide Drug Conjugate Sales and Growth Rate (2020-2025) & (K MT)
- Figure 101. South Africa Peptide Drug Conjugate Market Size and Growth Rate (2020-2025) & (M USD)
- Figure 102. Global Peptide Drug Conjugate Production Market Share by Region (2020-2025)
- Figure 103. North America Peptide Drug Conjugate Production (K MT) Growth Rate

(2020-2025)

Figure 104. Europe Peptide Drug Conjugate Production (K MT) Growth Rate

(2020-2025)

Figure 105. Japan Peptide Drug Conjugate Production (K MT) Growth Rate

(2020-2025)

Figure 106. China Peptide Drug Conjugate Production (K MT) Growth Rate (2020-2025)

Figure 107. Global Peptide Drug Conjugate Sales Forecast by Volume (2020-2035) &

(K MT)

Figure 108. Global Peptide Drug Conjugate Market Size Forecast by Value (2020-2035)

& (M USD)

Figure 109. Global Peptide Drug Conjugate Sales Market Share Forecast by Type

(2026-2035)

Figure 110. Global Peptide Drug Conjugate Market Share Forecast by Type

(2026-2035)

Figure 111. Global Peptide Drug Conjugate Sales Forecast by Application (2026-2035)

Figure 112. Global Peptide Drug Conjugate Market Share Forecast by Application

(2026-2035)

I would like to order

Product name: Global Peptide Drug Conjugate Market Research Report 2026(Status and Outlook)

Product link: <https://marketpublishers.com/r/GF72DFA428D0EN.html>

Price: US\$ 2,980.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GF72DFA428D0EN.html>